Eikon Therapeutics opens at $17.05, IPO priced at $18.00

Eikon Therapeutics (EIKN) priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. JPMorgan and Morgan Stanley are acting as joint book running managers for the offering. Eikon is a late-stage clinical biopharmaceutical company whose initial focus is oncology, where it says it is advancing a pipeline of drug candidates “targeting areas of high unmet need in large indications” for various cancers.